カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の頸椎症治療薬市場2023年：企業・地域・タイプ・用途別分析

■ 英語タイトル：Global Cervical Spondylosis Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR23JU615）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR23JU615
■ 発行日：2023年6月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品＆医療
■ ページ数：98
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥501,120見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥751,680見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,002,240見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の頸椎症治療薬市場2023年：企業・地域・タイプ・用途別分析]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

GlobalInfoResearchの最新の調査によると、世界の頸椎症治療薬の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の頸椎症治療薬市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、タイプ別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本レポートの主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- 頸椎症治療薬の成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

頸椎症治療薬市場はタイプと用途によって区分されます。2018年～2029年において、量と金額の観点からタイプ別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメント
・NSAID、筋弛緩薬、抗てんかん薬、抗うつ薬

用途別セグメント
・病院、クリニック、ドラッグストア

主要な市場プレーヤー
・Johnson & Johnson、BASF、IOLCP、Pfizer、Hisamitsu Pharmaceutical、Tianjin Shike Pharmaceutical Co.,Ltd.、Renhe Pharmacy Co.,Ltd.、Dr. Reddy's Laboratories

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、頸椎症治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な頸椎症治療薬メーカーの企業概要、2019年～2022年までの頸椎症治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な頸椎症治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別頸椎症治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの頸椎症治療薬のタイプ別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での頸椎症治療薬市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および頸椎症治療薬の産業チェーンを掲載しています。
・第14、15章では、頸椎症治療薬の販売チャネル、販売業者、顧客、調査結果について説明します。

***** 目次(一部) *****

・市場概要
- 頸椎症治療薬の概要
- タイプ別分析（2018年vs2022年vs2029年）：NSAID、筋弛緩薬、抗てんかん薬、抗うつ薬
- 用途別分析（2018年vs2022年vs2029年）：病院、クリニック、ドラッグストア
- 世界の頸椎症治療薬市場規模・予測
- 世界の頸椎症治療薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Johnson & Johnson、BASF、IOLCP、Pfizer、Hisamitsu Pharmaceutical、Tianjin Shike Pharmaceutical Co.,Ltd.、Renhe Pharmacy Co.,Ltd.、Dr. Reddy's Laboratories
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・タイプ別分析2018年-2029年：NSAID、筋弛緩薬、抗てんかん薬、抗うつ薬
・用途別分析2018年-2029年：病院、クリニック、ドラッグストア
・頸椎症治療薬の北米市場
- タイプ別市場規模2018年-2029年
- 用途別市場規模2018年-2029年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・頸椎症治療薬のヨーロッパ市場
- タイプ別市場規模2018年-2029年
- 用途別市場規模2018年-2029年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・頸椎症治療薬のアジア市場
- タイプ別市場規模2018年-2029年
- 用途別市場規模2018年-2029年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・頸椎症治療薬の南米市場
- タイプ別市場規模2018年-2029年
- 用途別市場規模2018年-2029年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・頸椎症治療薬の中東・アフリカ市場
- タイプ別市場規模2018年-2029年
- 用途別市場規模2018年-2029年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

According to our (Global Info Research) latest study, the global Cervical Spondylosis Drugs market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The prognosis for people with spondylosis depends on the severity of symptoms and the part of the spine affected. Many patients are able to improve or control their condition with medication.
This report is a detailed and comprehensive analysis for global Cervical Spondylosis Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Cervical Spondylosis Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Cervical Spondylosis Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Cervical Spondylosis Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Cervical Spondylosis Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Cervical Spondylosis Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Cervical Spondylosis Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, BASF, IOLCP, Pfizer and Hisamitsu Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Cervical Spondylosis Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
NSAIDs
Muscle Relaxants
Anti-epileptic Drugs
Antidepressants
Market segment by Application
Hospital
Clinic
Drugstore
Major players covered
Johnson & Johnson
BASF
IOLCP
Pfizer
Hisamitsu Pharmaceutical
Tianjin Shike Pharmaceutical Co.,Ltd.
Renhe Pharmacy Co.,Ltd.
Dr. Reddy’s Laboratories
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Cervical Spondylosis Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Cervical Spondylosis Drugs, with price, sales, revenue and global market share of Cervical Spondylosis Drugs from 2018 to 2023.
Chapter 3, the Cervical Spondylosis Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cervical Spondylosis Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Cervical Spondylosis Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Cervical Spondylosis Drugs.
Chapter 14 and 15, to describe Cervical Spondylosis Drugs sales channel, distributors, customers, research findings and conclusion.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Product Overview and Scope of Cervical Spondylosis Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Cervical Spondylosis Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 NSAIDs
1.3.3 Muscle Relaxants
1.3.4 Anti-epileptic Drugs
1.3.5 Antidepressants
1.4 Market Analysis by Application
1.4.1 Overview: Global Cervical Spondylosis Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Drugstore
1.5 Global Cervical Spondylosis Drugs Market Size & Forecast
1.5.1 Global Cervical Spondylosis Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Cervical Spondylosis Drugs Sales Quantity (2018-2029)
1.5.3 Global Cervical Spondylosis Drugs Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Johnson & Johnson
2.1.1 Johnson & Johnson Details
2.1.2 Johnson & Johnson Major Business
2.1.3 Johnson & Johnson Cervical Spondylosis Drugs Product and Services
2.1.4 Johnson & Johnson Cervical Spondylosis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Johnson & Johnson Recent Developments/Updates
2.2 BASF
2.2.1 BASF Details
2.2.2 BASF Major Business
2.2.3 BASF Cervical Spondylosis Drugs Product and Services
2.2.4 BASF Cervical Spondylosis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 BASF Recent Developments/Updates
2.3 IOLCP
2.3.1 IOLCP Details
2.3.2 IOLCP Major Business
2.3.3 IOLCP Cervical Spondylosis Drugs Product and Services
2.3.4 IOLCP Cervical Spondylosis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 IOLCP Recent Developments/Updates
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Cervical Spondylosis Drugs Product and Services
2.4.4 Pfizer Cervical Spondylosis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Pfizer Recent Developments/Updates
2.5 Hisamitsu Pharmaceutical
2.5.1 Hisamitsu Pharmaceutical Details
2.5.2 Hisamitsu Pharmaceutical Major Business
2.5.3 Hisamitsu Pharmaceutical Cervical Spondylosis Drugs Product and Services
2.5.4 Hisamitsu Pharmaceutical Cervical Spondylosis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Hisamitsu Pharmaceutical Recent Developments/Updates
2.6 Tianjin Shike Pharmaceutical Co.,Ltd.
2.6.1 Tianjin Shike Pharmaceutical Co.,Ltd. Details
2.6.2 Tianjin Shike Pharmaceutical Co.,Ltd. Major Business
2.6.3 Tianjin Shike Pharmaceutical Co.,Ltd. Cervical Spondylosis Drugs Product and Services
2.6.4 Tianjin Shike Pharmaceutical Co.,Ltd. Cervical Spondylosis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Tianjin Shike Pharmaceutical Co.,Ltd. Recent Developments/Updates
2.7 Renhe Pharmacy Co.,Ltd.
2.7.1 Renhe Pharmacy Co.,Ltd. Details
2.7.2 Renhe Pharmacy Co.,Ltd. Major Business
2.7.3 Renhe Pharmacy Co.,Ltd. Cervical Spondylosis Drugs Product and Services
2.7.4 Renhe Pharmacy Co.,Ltd. Cervical Spondylosis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Renhe Pharmacy Co.,Ltd. Recent Developments/Updates
2.8 Dr. Reddy’s Laboratories
2.8.1 Dr. Reddy’s Laboratories Details
2.8.2 Dr. Reddy’s Laboratories Major Business
2.8.3 Dr. Reddy’s Laboratories Cervical Spondylosis Drugs Product and Services
2.8.4 Dr. Reddy’s Laboratories Cervical Spondylosis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Dr. Reddy’s Laboratories Recent Developments/Updates
3 Competitive Environment: Cervical Spondylosis Drugs by Manufacturer
3.1 Global Cervical Spondylosis Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Cervical Spondylosis Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Cervical Spondylosis Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Cervical Spondylosis Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Cervical Spondylosis Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Cervical Spondylosis Drugs Manufacturer Market Share in 2022
3.5 Cervical Spondylosis Drugs Market: Overall Company Footprint Analysis
3.5.1 Cervical Spondylosis Drugs Market: Region Footprint
3.5.2 Cervical Spondylosis Drugs Market: Company Product Type Footprint
3.5.3 Cervical Spondylosis Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Cervical Spondylosis Drugs Market Size by Region
4.1.1 Global Cervical Spondylosis Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Cervical Spondylosis Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Cervical Spondylosis Drugs Average Price by Region (2018-2029)
4.2 North America Cervical Spondylosis Drugs Consumption Value (2018-2029)
4.3 Europe Cervical Spondylosis Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Cervical Spondylosis Drugs Consumption Value (2018-2029)
4.5 South America Cervical Spondylosis Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Cervical Spondylosis Drugs Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Cervical Spondylosis Drugs Sales Quantity by Type (2018-2029)
5.2 Global Cervical Spondylosis Drugs Consumption Value by Type (2018-2029)
5.3 Global Cervical Spondylosis Drugs Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Cervical Spondylosis Drugs Sales Quantity by Application (2018-2029)
6.2 Global Cervical Spondylosis Drugs Consumption Value by Application (2018-2029)
6.3 Global Cervical Spondylosis Drugs Average Price by Application (2018-2029)
7 North America
7.1 North America Cervical Spondylosis Drugs Sales Quantity by Type (2018-2029)
7.2 North America Cervical Spondylosis Drugs Sales Quantity by Application (2018-2029)
7.3 North America Cervical Spondylosis Drugs Market Size by Country
7.3.1 North America Cervical Spondylosis Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Cervical Spondylosis Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Cervical Spondylosis Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Cervical Spondylosis Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Cervical Spondylosis Drugs Market Size by Country
8.3.1 Europe Cervical Spondylosis Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Cervical Spondylosis Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Cervical Spondylosis Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Cervical Spondylosis Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Cervical Spondylosis Drugs Market Size by Region
9.3.1 Asia-Pacific Cervical Spondylosis Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Cervical Spondylosis Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Cervical Spondylosis Drugs Sales Quantity by Type (2018-2029)
10.2 South America Cervical Spondylosis Drugs Sales Quantity by Application (2018-2029)
10.3 South America Cervical Spondylosis Drugs Market Size by Country
10.3.1 South America Cervical Spondylosis Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Cervical Spondylosis Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Cervical Spondylosis Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Cervical Spondylosis Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Cervical Spondylosis Drugs Market Size by Country
11.3.1 Middle East & Africa Cervical Spondylosis Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Cervical Spondylosis Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Cervical Spondylosis Drugs Market Drivers
12.2 Cervical Spondylosis Drugs Market Restraints
12.3 Cervical Spondylosis Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Cervical Spondylosis Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Cervical Spondylosis Drugs
13.3 Cervical Spondylosis Drugs Production Process
13.4 Cervical Spondylosis Drugs Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Cervical Spondylosis Drugs Typical Distributors
14.3 Cervical Spondylosis Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Cervical Spondylosis Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Cervical Spondylosis Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 4. Johnson & Johnson Major Business
Table 5. Johnson & Johnson Cervical Spondylosis Drugs Product and Services
Table 6. Johnson & Johnson Cervical Spondylosis Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Johnson & Johnson Recent Developments/Updates
Table 8. BASF Basic Information, Manufacturing Base and Competitors
Table 9. BASF Major Business
Table 10. BASF Cervical Spondylosis Drugs Product and Services
Table 11. BASF Cervical Spondylosis Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. BASF Recent Developments/Updates
Table 13. IOLCP Basic Information, Manufacturing Base and Competitors
Table 14. IOLCP Major Business
Table 15. IOLCP Cervical Spondylosis Drugs Product and Services
Table 16. IOLCP Cervical Spondylosis Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. IOLCP Recent Developments/Updates
Table 18. Pfizer Basic Information, Manufacturing Base and Competitors
Table 19. Pfizer Major Business
Table 20. Pfizer Cervical Spondylosis Drugs Product and Services
Table 21. Pfizer Cervical Spondylosis Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Pfizer Recent Developments/Updates
Table 23. Hisamitsu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 24. Hisamitsu Pharmaceutical Major Business
Table 25. Hisamitsu Pharmaceutical Cervical Spondylosis Drugs Product and Services
Table 26. Hisamitsu Pharmaceutical Cervical Spondylosis Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Hisamitsu Pharmaceutical Recent Developments/Updates
Table 28. Tianjin Shike Pharmaceutical Co.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 29. Tianjin Shike Pharmaceutical Co.,Ltd. Major Business
Table 30. Tianjin Shike Pharmaceutical Co.,Ltd. Cervical Spondylosis Drugs Product and Services
Table 31. Tianjin Shike Pharmaceutical Co.,Ltd. Cervical Spondylosis Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Tianjin Shike Pharmaceutical Co.,Ltd. Recent Developments/Updates
Table 33. Renhe Pharmacy Co.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 34. Renhe Pharmacy Co.,Ltd. Major Business
Table 35. Renhe Pharmacy Co.,Ltd. Cervical Spondylosis Drugs Product and Services
Table 36. Renhe Pharmacy Co.,Ltd. Cervical Spondylosis Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Renhe Pharmacy Co.,Ltd. Recent Developments/Updates
Table 38. Dr. Reddy's Laboratories Basic Information, Manufacturing Base and Competitors
Table 39. Dr. Reddy's Laboratories Major Business
Table 40. Dr. Reddy's Laboratories Cervical Spondylosis Drugs Product and Services
Table 41. Dr. Reddy's Laboratories Cervical Spondylosis Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Dr. Reddy's Laboratories Recent Developments/Updates
Table 43. Global Cervical Spondylosis Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 44. Global Cervical Spondylosis Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 45. Global Cervical Spondylosis Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 46. Market Position of Manufacturers in Cervical Spondylosis Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 47. Head Office and Cervical Spondylosis Drugs Production Site of Key Manufacturer
Table 48. Cervical Spondylosis Drugs Market: Company Product Type Footprint
Table 49. Cervical Spondylosis Drugs Market: Company Product Application Footprint
Table 50. Cervical Spondylosis Drugs New Market Entrants and Barriers to Market Entry
Table 51. Cervical Spondylosis Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 52. Global Cervical Spondylosis Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 53. Global Cervical Spondylosis Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 54. Global Cervical Spondylosis Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 55. Global Cervical Spondylosis Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 56. Global Cervical Spondylosis Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 57. Global Cervical Spondylosis Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 58. Global Cervical Spondylosis Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 59. Global Cervical Spondylosis Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 60. Global Cervical Spondylosis Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 61. Global Cervical Spondylosis Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 62. Global Cervical Spondylosis Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 63. Global Cervical Spondylosis Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 64. Global Cervical Spondylosis Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 65. Global Cervical Spondylosis Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 66. Global Cervical Spondylosis Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 67. Global Cervical Spondylosis Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 68. Global Cervical Spondylosis Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 69. Global Cervical Spondylosis Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 70. North America Cervical Spondylosis Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 71. North America Cervical Spondylosis Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 72. North America Cervical Spondylosis Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 73. North America Cervical Spondylosis Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 74. North America Cervical Spondylosis Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 75. North America Cervical Spondylosis Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 76. North America Cervical Spondylosis Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 77. North America Cervical Spondylosis Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 78. Europe Cervical Spondylosis Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Europe Cervical Spondylosis Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Europe Cervical Spondylosis Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 81. Europe Cervical Spondylosis Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 82. Europe Cervical Spondylosis Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 83. Europe Cervical Spondylosis Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 84. Europe Cervical Spondylosis Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 85. Europe Cervical Spondylosis Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 86. Asia-Pacific Cervical Spondylosis Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 87. Asia-Pacific Cervical Spondylosis Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 88. Asia-Pacific Cervical Spondylosis Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 89. Asia-Pacific Cervical Spondylosis Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 90. Asia-Pacific Cervical Spondylosis Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 91. Asia-Pacific Cervical Spondylosis Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 92. Asia-Pacific Cervical Spondylosis Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 93. Asia-Pacific Cervical Spondylosis Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 94. South America Cervical Spondylosis Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 95. South America Cervical Spondylosis Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 96. South America Cervical Spondylosis Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 97. South America Cervical Spondylosis Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 98. South America Cervical Spondylosis Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 99. South America Cervical Spondylosis Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 100. South America Cervical Spondylosis Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 101. South America Cervical Spondylosis Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 102. Middle East & Africa Cervical Spondylosis Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 103. Middle East & Africa Cervical Spondylosis Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 104. Middle East & Africa Cervical Spondylosis Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 105. Middle East & Africa Cervical Spondylosis Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 106. Middle East & Africa Cervical Spondylosis Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 107. Middle East & Africa Cervical Spondylosis Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 108. Middle East & Africa Cervical Spondylosis Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 109. Middle East & Africa Cervical Spondylosis Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 110. Cervical Spondylosis Drugs Raw Material
Table 111. Key Manufacturers of Cervical Spondylosis Drugs Raw Materials
Table 112. Cervical Spondylosis Drugs Typical Distributors
Table 113. Cervical Spondylosis Drugs Typical Customers
List of Figures
Figure 1. Cervical Spondylosis Drugs Picture
Figure 2. Global Cervical Spondylosis Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Cervical Spondylosis Drugs Consumption Value Market Share by Type in 2022
Figure 4. NSAIDs Examples
Figure 5. Muscle Relaxants Examples
Figure 6. Anti-epileptic Drugs Examples
Figure 7. Antidepressants Examples
Figure 8. Global Cervical Spondylosis Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Cervical Spondylosis Drugs Consumption Value Market Share by Application in 2022
Figure 10. Hospital Examples
Figure 11. Clinic Examples
Figure 12. Drugstore Examples
Figure 13. Global Cervical Spondylosis Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Cervical Spondylosis Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Cervical Spondylosis Drugs Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Cervical Spondylosis Drugs Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Cervical Spondylosis Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Cervical Spondylosis Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Cervical Spondylosis Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Cervical Spondylosis Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Cervical Spondylosis Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Cervical Spondylosis Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Cervical Spondylosis Drugs Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Cervical Spondylosis Drugs Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Cervical Spondylosis Drugs Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Cervical Spondylosis Drugs Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Cervical Spondylosis Drugs Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Cervical Spondylosis Drugs Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Cervical Spondylosis Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Cervical Spondylosis Drugs Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Cervical Spondylosis Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Cervical Spondylosis Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Cervical Spondylosis Drugs Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Cervical Spondylosis Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Cervical Spondylosis Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Cervical Spondylosis Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Cervical Spondylosis Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Cervical Spondylosis Drugs Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Cervical Spondylosis Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Cervical Spondylosis Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Cervical Spondylosis Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Cervical Spondylosis Drugs Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Cervical Spondylosis Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Cervical Spondylosis Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Cervical Spondylosis Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Cervical Spondylosis Drugs Consumption Value Market Share by Region (2018-2029)
Figure 55. China Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Cervical Spondylosis Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Cervical Spondylosis Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Cervical Spondylosis Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Cervical Spondylosis Drugs Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Cervical Spondylosis Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Cervical Spondylosis Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Cervical Spondylosis Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Cervical Spondylosis Drugs Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Cervical Spondylosis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Cervical Spondylosis Drugs Market Drivers
Figure 76. Cervical Spondylosis Drugs Market Restraints
Figure 77. Cervical Spondylosis Drugs Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Cervical Spondylosis Drugs in 2022
Figure 80. Manufacturing Process Analysis of Cervical Spondylosis Drugs
Figure 81. Cervical Spondylosis Drugs Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source

※参考情報

頸椎症は、頸椎（首の骨）の変性疾患であり、加齢や過度の使用、外傷などによって引き起こされることが多いです。この疾患は、椎間板の変性や骨棘の形成、脊髄や神経根の圧迫を引き起こし、痛み、しびれ、筋力低下などの症状をもたらします。頸椎症に伴う症状の軽減や治療のためには、さまざまな治療薬が使用されます。

頸椎症治療薬の主要な特徴は、症状の緩和効果にあります。これらの薬剤は、痛みや炎症を抑えるために処方されることが一般的です。疼痛管理は、患者の生活の質を向上させるために非常に重要です。頸椎症に伴う痛みは、慢性的なものであることが多く、日常生活に支障をきたすため、適切な治療が求められます。

頸椎症に使用される薬剤は主に以下のような種類に分類されます。まず、非ステロイド性抗炎症薬（NSAIDs）は、頸椎症治療の第一選択薬として広く用いられています。これらの薬剤は、炎症を抑え、痛みを軽減する作用があり、オプチウム系の薬剤通販や医療機関で広く処方されています。代表的なNSAIDsには、イブプロフェンやナプロキセンなどがあります。これらは、比較的副作用が少なく、短期間の使用に適しています。

次に、筋弛緩薬も頸椎症の治療に用いられます。筋弛緩薬は、筋肉の緊張を和らげることで、痛みを緩和する効果があります。頸椎症の患者は、筋肉の緊張によってさらに痛みが強くなることがあるため、筋弛緩薬は有効な選択肢となります。代表的な筋弛緩薬には、メトカルバモールやクロルゾキサゾンがあります。

さらに、ステロイド薬も症状の重い患者に対して使用されることがあります。ステロイドは炎症を強力に抑えるため、痛みの軽減に非常に効果的です。ただし、長期使用には副作用が伴うため、通常は慎重に使用されるべきです。ステロイド薬は、口服薬や注射剤として使用されます。

神経障害性疼痛に対しては、抗うつ薬や抗てんかん薬が効果的な場合があります。たとえば、ガバぺンチンやデュロキセチンなどは、神経因性疼痛に対する効果が報告されています。これらの薬剤は、頸椎症に伴うしびれや痛みに対して、異なるメカニズムで作用するため、多角的なアプローチが可能です。

痛みの治療に加えて、頸椎症のリハビリテーションも重要です。物理療法や運動療法、姿勢改善などが取り入れられますが、これらは薬物治療と組み合わせて行われることで、より効果を高めることができます。治療の初期段階では、痛みを軽減することが優先されますが、根本的な改善を目指すためには、リハビリテーションが欠かせません。

最近では、頸椎症の治療において、ヘルスケア技術の進展も見逃せません。低侵襲技術や新たな治療法が次々と開発され、患者の負担を軽減しています。たとえば、超音波療法や電気刺激療法などは、痛みの緩和に一定の効果を示すことがあります。加えて、バイオフィードバックや姿勢分析など、技術を活用した新しいアプローチも普及しています。

最後に、頸椎症治療においては患者の生活習慣が密接に関わっています。運動習慣や体重管理、ストレスの軽減が症状の改善につながることが多いため、治療に併せて生活習慣の見直しも重要です。治療薬の効果を最大限に高めるためには、医師や理学療法士と協力しながら、個々の患者に合わせた治療計画を立て、それを実行していくことが肝要です。

頸椎症の治療については、薬物以外にも多様な選択肢があり、患者ごとの症状や生活状況に応じたきめ細やかなアプローチが必要です。薬剤の特性を理解し、正しく使用することで、多くの患者が痛みの軽減と生活の質の向上を実現することができるでしょう。今後、さらなる研究や技術の進展によって、より効果的な治療法が開発されることが期待されます。


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の心筋梗塞治療薬市場2023年：企業・地域・タイプ・用途別分析
  • 世界の使い捨て式子宮頸管熟成バルーン市場2023年：企業・地域・タイプ・用途別分析
  • 世界のGLP-1RA医薬品市場2023年：企業・地域・タイプ・用途別分析
  • 世界の単回使用子宮頸部拡張器カナルダイレーター市場2023年：企業・地域・タイプ・用途別分析
  • 世界の神経芽腫に対する化学療法薬市場2023年：企業・地域・タイプ・用途別分析
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR23JU615 )"世界の頸椎症治療薬市場2023年：企業・地域・タイプ・用途別分析" (英文：Global Cervical Spondylosis Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。